About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

15.21 +0.26 (+1.71%)

Streaming Delayed Price Updated: 2:55 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex ↗

December 02, 2023

The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November.

Via Talk Markets

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

GH Research, Compass Pathways Among Top Psychedelic Movers Of Today ↗

November 23, 2023

Via Benzinga

GH Research Drags Down Psychedelic Drug Stocks Index By 7% ↗

November 23, 2023

The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week.

Via Talk Markets

Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 22, 2023

Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.

Via Benzinga

HP, Iridium Communications And Other Big Stocks Moving Higher On Wednesday ↗

November 22, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Wednesday. Shares of HP Inc. (NYSE: HPQ) gained during Wednesday’s session following quarterly results.

Via Benzinga

Topics Stocks

GH Research: Steady Expenses And $229M Cash Position For 2026 Runway ↗

November 14, 2023

The clinical-stage psychedelics biotech GH Research PLC (NASDAQ: GHRS) reported its financial results for Q3 2023 ended September 30, showing:

Via Benzinga

Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗

November 12, 2023

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?

Via Benzinga

Topics Initial Public Offering

Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart ↗

November 11, 2023

Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on...

Via Talk Markets

GH Research Reports Third Quarter Financial Results and Provides Business Updates

November 09, 2023

From GH Research PLC

Via GlobeNewswire

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22% ↗

November 05, 2023

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances.

Via Talk Markets

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

General Dynamics, Microsoft, Waste Management And Other Big Stocks Moving Higher On Wednesday ↗

October 25, 2023

U.S. stocks traded lower, with the Nasdaq Composite falling more than 1% on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

Psychedelic-Compound-Based Drug Stocks Continue To Fall ↗

October 15, 2023

The 5 constituents in our Psychedelic Drug Stocks Index were down 10.1% this week (-6.3% last week) and are now down 39.2% since the end of July.

Via Talk Markets

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

Major Psychedelic Drug Stocks Continued To Decline This Week ↗

October 06, 2023

A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news.

Via Talk Markets

GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold ↗

October 02, 2023

After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s (NASDAQ: GHRS) Investigational New Drug (IND) application for a Phase 1 clinical trial of proprietary...

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

September Summary: Largest Psychedelic Drug Stocks Dropped 14% ↗

October 01, 2023

Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining...

Via Talk Markets

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

September 29, 2023

From GH Research PLC

Via GlobeNewswire

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗

September 24, 2023

With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...

Via Talk Markets

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗

September 18, 2023

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

Via Benzinga

4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗

September 17, 2023

4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...

Via Talk Markets

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗

September 10, 2023

The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD.

Via Talk Markets

6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗

September 05, 2023

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

GH Research PLC - Ordinary Shares (NQ:GHRS)

All News about GH Research PLC - Ordinary Shares

Sections

Services

Contact Information

Follow Us